Figure 8. Spacer length impacts VG peptide efficacy against both HPIV3 clinical isolates (CI) and NiV.

(a) Vero cell monolayers were infected with HPIV3 at a multiplicity of infection (m.o.i.) of 2.5 × 10⁻³, in the presence of increasing concentrations of the peptide. After a 90-min incubation at 37 °C, cells were overlaid with methylcellulose, and plaques were immunostained and counted after 24 h. The percent inhibition of viral entry (compared to results for control cells infected in the absence of inhibitors) is shown as a function of the (log-scale) concentration of peptide (n = 3 separate experiments). (b) Vero cell monolayers were infected with wild type NiV at an m.o.i. of 2.5 × 10⁻³ in the presence of increasing concentrations of peptides. After 1 h incubation at 37 °C, cells were overlaid with methylcellulose, and plaques were stained and counted after 96 h. The percent inhibition of viral entry (compared to results for control cells infected in the absence of inhibitors) is shown as a function of the (log-scale) concentration of peptide. Data points are means ± s.d. (n = 6 separate experiments).